Verification note
Regimen is a GLP-1 tracker app for iPhone and Android that logs doses, weight and side effects, whichever pharmacy fills the prescription.
Provincial drug plan coverage, special authority criteria, and private pricing change frequently and vary by province. Verify current status with your provincial formulary and at canada.ca/health-canada before making treatment decisions.
GLP-1 medications are available in Canada, but provincial drug plan coverage is one of the most confusing aspects of the Canadian healthcare system to navigate. What’s covered, what you pay out of pocket, and what your options are if your plan doesn’t cover it all depends on your province, your diagnosis, and your insurance plan.
Here’s how it actually works.
What Health Canada Has Approved
| Medication | Active ingredient | Approved indication |
|---|---|---|
| Ozempic | Semaglutide 0.5mg, 1mg, 2mg | Type 2 diabetes |
| Wegovy | Semaglutide 2.4mg | Chronic weight management (BMI 30+, or 27+ with comorbidity) |
| Mounjaro | Tirzepatide | Type 2 diabetes |
| Zepbound | Tirzepatide | Chronic weight management |
| Rybelsus | Oral semaglutide | Type 2 diabetes |
All are Health Canada approved. The access and coverage story varies significantly by province.
Provincial Drug Plan Coverage
Coverage for GLP-1s varies more by province than almost any other drug class in Canada. Here’s the current picture:
Ontario (ODB):
- Ozempic for type 2 diabetes: covered for eligible patients; the plan pays the generic semaglutide price, $78.14 a pen
- Wegovy for obesity: limited/inconsistent coverage as of 2026. Ontario has been slower than other provinces to establish formal obesity coverage
- Private drug plans in Ontario vary by employer
British Columbia (PharmaCare):
- Ozempic for type 2 diabetes: covered under regular benefits
- Wegovy for obesity: coverage is restricted and requires special authority. Not routinely listed
- Fair PharmaCare applies income-based deductibles
Alberta (Alberta Blue Cross):
- Broader coverage than most provinces for both diabetes and obesity indications
- Wegovy can be covered under the Non-Group Benefits plan with prior authorization
- Alberta has been more progressive on obesity pharmacotherapy coverage
Manitoba, Saskatchewan: Diabetes indication generally covered; obesity indication limited.
Quebec (RAMQ):
- Ozempic for type 2 diabetes: listed; RAMQ pays the lowest price, the generic’s $78.14 a pen
- Wegovy: not yet consistently covered for obesity
Private employer insurance: Most employer-sponsored drug plans cover GLP-1s for type 2 diabetes. Obesity coverage is plan-specific. Check your policy’s formulary and whether prior authorization is required.
What You Pay Without Coverage
Last checked: October 2026. Ozempic and generic semaglutide are provincial formulary list prices per pen (Ontario ODB e-Formulary, Quebec RAMQ). Wegovy and Mounjaro are on no provincial formulary, so they have no official price: their figures are pharmacy cash ranges, and the spread is wide enough that it is worth calling two or three.
| Medication | Price without coverage |
|---|---|
| Ozempic | $195.06-227.94 CAD a pen (formulary list price) |
| Wegovy | $400-570 CAD a month (pharmacy range) |
| Mounjaro | $300-650 CAD a month (pharmacy range) |
| Generic semaglutide (Dr. Reddy’s, Apotex and others) | $78.14 CAD a pen (formulary list price) |
Pharmacy cash prices for Wegovy and Mounjaro genuinely vary this much by province and by chain.
Generic semaglutide has arrived in Canada
This is the biggest change to Canadian GLP-1 pricing in years and most guides have not caught up. On 28 April 2026, Health Canada authorised the first generic semaglutide, from Dr. Reddy’s Laboratories, making Canada the first G7 country to do so. It is approved for type 2 diabetes.
There is a practical catch when you go to ask for it: it does not have a consumer brand name in Canada. In Health Canada’s Drug Product Database the Dr. Reddy’s product is listed as Semaglutide Injection, DINs 02567806 and 02567814, marketed since 6 May 2026. Asking a pharmacist for a brand name you read online will not get you anywhere.
It is also no longer alone. Apotex’s APO-Semaglutide Injection has been marketed since 14 May 2026, and several more sponsors have been authorised since, including Aspen and Sandoz, plus Apotex’s Sevmia, which Health Canada approved on 29 June 2026 for chronic weight management rather than diabetes. Authorised is not the same as on the shelf, so the question for your pharmacy is which generic they can actually dispense.
Ontario and Quebec now list generic semaglutide at $78.14 a pen, against $195.06 to $227.94 for Ozempic, and both pay the generic price even when Ozempic is dispensed. Cash prices are set by each pharmacy, so ask your pharmacist what they can dispense and what your plan covers.
Manufacturer savings programs also exist: Novo Nordisk and Eli Lilly both run Canadian patient assistance programs. Check the brand’s website for eligibility.
Getting a Prescription
For diabetes: your GP, endocrinologist, or internist can prescribe.
For obesity (Wegovy/Zepbound): you’ll typically need a documented BMI of 30 or higher, or 27 or higher with a comorbidity like hypertension or sleep apnea. Weight management clinics and endocrinologists are the most common prescribers for the obesity indication. Some GPs prescribe directly.
Telehealth options: Weight management telehealth services have expanded significantly in Canada post-pandemic. Several platforms offer GLP-1 prescriptions with follow-up care. Look for services operating in your province.
Compounded GLP-1 in Canada
Canada’s compounding pharmacy framework operates differently from the US. Canadian compounding pharmacies are regulated provincially, and some have continued to offer compounded semaglutide and tirzepatide preparations even as US availability changed.
Availability of compounded GLP-1 varies significantly by province and pharmacy. Some provinces have clearer guidance than others. This route typically requires a prescription and a compounding pharmacy with relevant experience.
If cost is the primary barrier and brand-name coverage isn’t available, this is worth discussing with a provider familiar with Canadian compounding pharmacy access.
Tracking Your GLP-1 Protocol
Whether you’re on a brand-name pen or a compounded vial, tracking your GLP-1 dose and your health metrics together is what lets you know what’s working.
If you are still choosing an app, the best GLP-1 tracker apps comparison covers the free tiers and what each one actually tracks.
The GLP-1 dose calculator calculates your exact injection volume for any compounded semaglutide or tirzepatide concentration. Free, no account required.
Frequently Asked Questions
Is there a generic Ozempic in Canada?
Yes. Health Canada authorised the first generic semaglutide on 28 April 2026, making Canada the first G7 country to approve one. It has no separate brand name here: in Health Canada’s Drug Product Database the Dr. Reddy’s product is listed simply as Semaglutide Injection (DINs 02567806 and 02567814), and it has been marketed since 6 May 2026 for type 2 diabetes. It is no longer the only one. Apotex’s APO-Semaglutide Injection has been marketed since 14 May 2026, and further sponsors have since been authorised, including Apotex’s Sevmia, which Health Canada approved on 29 June 2026 for chronic weight management. First generics typically price well below the brand under the pan-Canadian Pharmaceutical Alliance structure, but shelf pricing depends on provincial listing decisions. Ask your pharmacist which generic they stock.
How much does Ozempic cost in Canada without insurance?
Without insurance the pharmacy sets the cash price, so it is worth calling two or three. As a benchmark, provincial formularies list Ozempic at $195.06 (Quebec) to $227.94 (Ontario) CAD a pen, and generic semaglutide at $78.14 a pen (last checked October 2026).
Do provincial drug plans cover GLP-1 medications in Canada?
For type 2 diabetes, generally yes, subject to each province’s criteria and often prior authorization. For weight management, almost never: provincial plans do not routinely cover GLP-1s for obesity. Private employer plans vary by policy, so check the formulary and whether prior authorization is required.
Do I need a specialist to be prescribed a GLP-1 in Canada?
Not usually. For diabetes, your GP, endocrinologist or internist can prescribe. For obesity, you will typically need a documented BMI of 30 or higher, or 27 or higher with a comorbidity such as hypertension or sleep apnea. Weight management clinics and endocrinologists are the most common prescribers for that indication, though some GPs prescribe directly.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Ready to track your GLP-1?
- Smart reminders so you never miss a dose
- Track weight, photos, and progress over time
- Medication level curves for every compound
